Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.

To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.

The purpose of the "Compare-TAVI" organization is to ensure a continuous comparison of the TAVI-valves implanted, and to monitor long-term valve performances. Purpose of present study: To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia. Hypotheses: 1. Evolut FX is non-inferior to Edwards Sapien 3 Resilia with regard to the combined endpoint (death, stroke, moderate/severe aortic regurgitation, moderate/severe valve deterioration) between the two valves being compared. 2. There is no difference between valves in secondary safety and efficacy endpoints (see below) 3. There is no difference in Aortic Regurgitation fraction (ARF) and Effective Orifice Area (EOA) measured by CMR (CMR-substudy, N=166) 4. There is no difference in EOA measured invasively during dobutamine stress (hemodynamic substudy, N=440). 5. There is no difference in occurrence of Hypoathenuated Leaflet Thickening (HALT) measured by CT (CT-substudy, N=778).